AI
SGMT icon

Atom Investors’s Sagimet Biosciences SGMT Stock Holding History

Atom Investors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67M Buy
+346,018
New +$2.35M 0.24% 107
2025
Q3 		– Sell
-20,393
Closed -$155K – 788
2025
Q2 		$155K Buy
+20,393
New +$86.1K 0.01% 528

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Atom Investors's SGMT Position: Q2 2026 in Review

Atom Investors opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 346,018 shares worth $2.67M. The stake represents 0.24% of the portfolio and ranks #107 among its holdings. This is a return to the name: Atom Investors previously reported a position in SGMT as recently as Q2 2025.

Atom Investors first reported a position in SGMT in Q2 2025 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Atom Investors held 346,018 shares of Sagimet Biosciences worth $2.67M as of Q2 2026.
  • Sagimet Biosciences was a new Atom Investors position in Q2 2026.
  • Sagimet Biosciences made up 0.24% of Atom Investors's portfolio in Q2 2026, its #107 holding.
  • Atom Investors first reported a position in Sagimet Biosciences in Q2 2025 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.